

**CLAIMS:**

1. A method for treating a neurodegenerative disorder or disease in which there is accumulation of misfolded and/or aggregated proteins, excluding prion-related diseases, said method comprising administering to an individual in need an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
2. A method in accordance with claim 1, wherein said neurodegenerative disease or disorder is selected from the group consisting of Huntington's disease, Alzheimer's disease and Parkinson's disease.
3. A method in accordance with claim 2, wherein said agent is Copolymer 1.
4. A method in accordance with claim 2, wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.
5. A method in accordance with claim 2, wherein said agent is T cells which have been activated by Copolymer 1.
6. A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease, Alzheimer's disease and Parkinson's disease, which comprises immunizing said patient with an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
7. A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease, Alzheimer's disease and Parkinson's disease, which

comprises administering to said patient in need a therapeutically effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

5 8. A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Alzheimer's disease, which comprises administering to an individual in need thereof an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related  
10 polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

9. A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Huntington's disease, which comprises administering to an individual in need thereof an effective amount of an agent selected from the group consisting of (i)  
15 Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

10. A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Parkinson's disease, which comprises administering to an individual in need  
20 thereof an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

11. A method for treatment of a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease,  
25 Alzheimer's disease and Parkinson's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for reducing disease progression in said patient.

12. A method for treatment of a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease, Alzheimer's disease and Parkinson's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for protection from neurodegeneration in said patient.
13. A method for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with Huntington's disease, Alzheimer's disease or Parkinson's disease, said method comprising administering to an individual in need an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
14. A method according to claim 13, wherein said active agent is Copolymer 1.
15. A pharmaceutical composition for treatment of a neurodegenerative disorder or disease in which there is accumulation of misfolded and/or aggregated proteins, excluding prion-related diseases, comprising a pharmaceutically acceptable carrier and an active agent selected from (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
16. A pharmaceutical composition according to claim 15, for reducing disease progression, and/or for protection from neurodegeneration, and/or protection from glutamate toxicity in a patient suffering from said neurodegenerative disorder or disease.
17. A pharmaceutical composition according to claim 15 or 16, wherein said neurodegenerative disease or disorder is Huntington's disease, Alzheimer's disease or Parkinson's disease.
18. A pharmaceutical composition according to claim 17, wherein said active agent is Copolymer 1.

19. Use of an active agent selected from (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii), for the manufacture of a medicament for treatment of a neurodegenerative disorder or disease in which there is accumulation of misfolded and/or aggregated proteins, excluding prion-related diseases.
20. Use according to claim 19, wherein said neurodegenerative disease or disorder is Huntington's disease, Alzheimer's disease and Parkinson's disease.
21. Use according to claim 20, wherein said active agent is Copolymer 1.
22. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, said pharmaceutical composition comprising an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide; and said packaging material includes a label that indicates that said agent is therapeutically effective for treating a neurodegenerative disease or disorder selected from Huntington's disease, Alzheimer's disease or Parkinson's disease.
23. An article of manufacture according to claim 22, wherein said agent is Copolymer 1.